Seeking Alpha

Leerink downgrades Synageva BioPharma, cites lack of visibility

  • Leerink downgrades Synageva BioPharma (GEVA) to Market Perform from Outperform.
  • Analyst Joseph Schwartz cites "lack of news flow and visibility into the market opportunity for sebelipase alfa."
  • Schwartz also says the stock may remain "relatively rangebound until ARISE pivotal trial data" due in H2 2014 or H1 2015.
  • Price target cut to $62 from $66.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)